Why the study?
Does Pazopanib show antitumor activity in patients with metastatic Alveolar Soft Part Sarcoma?
Does Pazopanib show antitumor activity in patients with metastatic Alveolar Soft Part Sarcoma?
Pazopanib demonstrates modest antitumor activity and manageable toxicity in patients with metastatic alveolar soft part sarcoma.
Answers are grounded in this paper and cite their sources.
Supports pazopanib consideration in metastatic ASPS; leaves open randomized confirmation of benefit.
Pazopanib showed modest antitumor activity with manageable toxicities for patients with metastatic ASPS.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: